Course InformationTherapautic Area: Oncology
Format(s): Meeting Reporter, Downloadable Transcript
Credit(s): 1.0 AMA PRA Category 1 Credit(s)™
Activity Dates: March 10, 2016-March 9, 2017
This CME program will focus on the new and emerging therapeutic options in the management of patients with metastatic melanoma that were presented at the 2016 Society of Melanoma Research Congress held in Boston, Massachusetts. The expert faculty will discuss the trials and science behind new combination therapies in comparison to singlet therapy treatment to improve response rates in patients with metastatic melanoma. Optimal strategies for developing comprehensive, multidisciplinary treatment plans that affect outcomes and quality of life will also be reviewed. At the conclusion of this educational offering, learners will have a better understanding of recent science as it relates to treatment options for patients with metastatic melanoma.
Oncologists, dermatologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with melanoma.
- Discuss diagnostic criteria, tumor characteristics, and treatment guidelines for the management of metastatic melanoma as presented at SMR 2016.
- Analyze clinical trial data for current and emerging combination therapeutics for the treatment of metastatic melanoma as presented at SMR 2016.
- Develop multidisciplinary treatment plans to improve outcomes and overall quality of life for patients with metastatic melanoma.
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Ryan Sullivan, MD||Consultant/Advisor: Amgen, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Merck & Co.; Novartis|
|Jeffrey Weber, MD||Consultant/Advisor: Amgen, Inc.; Novartis|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
Provided by AcademicCME
This CME activity has been supported by an independent educational grant from Amgen, Inc.